RAS Amplification as a Negative Predictor of Benefit from Anti‐EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer

BACKGROUND: RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (EGFRmAb). However, the clinical implications for RAS amplification (RASa) as a biomarker for anti‐EGFR therapy in CRC remain i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Schrock, Alexa B., Lee, Jessica K., Sandhu, Jaideep, Madison, Russell, Cho‐Phan, Cheryl, Snider, Jeremy W., Castellanos, Emily, Venstrom, Jeffrey M., Fakih, Marwan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2021
Aiheet:
Gastrointestinal Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176984/
https://ncbi.nlm.nih.gov/pubmed/33465286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13679
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia